2019 Taiwan Stroke Society Guideline for Intravenous Thrombolysis in Acute Ischemic Stroke Patients
陳志弘(Chih-Hung Chen)；謝函潔(Han-Chieh Hsieh)；宋昇峯(Sheng-Feng Sung)；謝鎮陽(Cheng-Yang Hsieh)；陳柏霖(Po-Lin Chen)；蔡力凱(Li-Kai Tsai)；黃虹瑜(Hung Yu Huang)；鄭建興(Jiann-Shing Jeng)；急性缺血中風靜脈血栓溶解治療指引共識小組(Taiwan Stroke Society Guideline Consensus Group)
acute ischemic stroke ； guideline ； thrombolysis ； thrombectomy
|Volume or Term/Year and Month of Publication||
1卷1期（2019 / 06 / 01）
1 - 22
Intravenous thrombolysis is still one of the most effective therapies for patients with acute ischemic stroke. Recombinant tissue-type plasminogen activator (rt-PA) has been approved for clinical use since 2002 in Taiwan. Previously, Taiwan Stroke Society has published the guidelines of intravenous thrombolysis for acute ischemic stroke patients in 2008 and 2013, respectively. Enhanced effort to increase intravenous rt-PA treatment for acute ischemic stroke patients in Taiwan can be observed, and the rate of treatment reached to 4-5% in recent years. However, the indication and treatment time of intravenous thrombolysis have been expanded recently. To provide the evidence-based recommendations, and standardize intravenous thrombolysis for acute ischemic stroke, the Taiwan Stroke Society Guideline Consensus Group revised the guideline. The guideline contains 5 issues, including intravenous rt-PA treatment for onset to needle time more than 3 hours, age over 80 years, mild or rapidly improving symptoms, pre-stroke use of anticoagulants, and probably endovascular thrombectomy for patients with large vessel occlusion.
醫藥衛生 > 外科